PepGen (PEPG) Net Cash Flow (2021 - 2026)
PepGen (PEPG) posted Net Cash Flow of -$18.4 million for Q1 2026, up 77.67% sequentially from -$82.3 million in Q4 2025, and down 217.71% YoY from $15.6 million in Q1 2025.
Analysis
PepGen (PEPG) Net Cash Flow (2021 - 2026) Analysis & Trends
PepGen has reported Net Cash Flow for 6 years, with the latest figure at -$18.4 million in Q1 2026.
- Quarterly Net Cash Flow fell 217.71% year-over-year to -$18.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.5 million (up 98.36% YoY) and the FY2025 annual result came in at $11.1 million, up 135.5% from the prior year.
- Net Cash Flow advanced to -$18.4 million in Q1 2026 per PEPG's latest filing, from -$82.3 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $107.7 million in Q3 2025 and troughed at -$82.3 million in Q4 2025.
- A 5-year average of -$5.3 million and a median of -$16.5 million in 2023 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2025: Net Cash Flow surged 1728.72% in 2022, then slumped 1249.85% in 2025.
- Over 5 years, Net Cash Flow stood at -$14.3 million in 2022, then slumped by 243.23% to -$49.0 million in 2023, then soared by 114.6% to $7.2 million in 2024, then plunged by 1249.85% to -$82.3 million in 2025, then surged by 77.67% to -$18.4 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$18.4 million, -$82.3 million, and $107.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -183.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 407.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -496,000.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.14 Mn |
| 10 | PepGen | 217.99 Mn | 217.99 Mn | - | -19.39 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -19.39 Mn |
| Mar 31, 2026 | -18.37 Mn |
| Dec 31, 2025 | -82.26 Mn |
| Sep 30, 2025 | 107.70 Mn |
| Jun 30, 2025 | -8.55 Mn |
| Mar 31, 2025 | -5.78 Mn |
| Dec 31, 2024 | 7.15 Mn |
| Sep 30, 2024 | -23.82 Mn |
| Jun 30, 2024 | -67.77 Mn |
| Mar 31, 2024 | 53.14 Mn |
| Dec 31, 2023 | -48.99 Mn |
| Sep 30, 2023 | -17.24 Mn |
| Jun 30, 2023 | -18.50 Mn |
| Mar 31, 2023 | -16.47 Mn |
| Dec 31, 2022 | -14.27 Mn |
| Sep 30, 2022 | -22.82 Mn |
| Jun 30, 2022 | 100.17 Mn |
| Mar 31, 2022 | -13.90 Mn |
| Dec 31, 2021 | -7.17 Mn |
| Sep 30, 2021 | 125.20 Mn |